Ablynx

Nanobody drug discovery and development partnership signed

Published in Biotech Law Weekly, August 20th, 2004

Ablynx, developer of Nanobodies, a new class of therapeutic antibodies, announced that they have entered into a drug discovery and development partnership with Procter & Gamble Pharmaceuticals, Inc., (P&GP), a subsidiary of The Procter & Gamble Company (PG).

Through this agreement, Ablynx will use its unique and patent protected Nanobody platform to discover and develop drug candidates against a G-protein coupled receptor (GPCR) target specified by P&GP.

Nanobodies are a novel class of therapeutics that combines the advantages of conventional antibodies with key features of small-molecule drugs. As the smallest functional fragment of naturally...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry